Dominari (DOMH) Projected to Post Quarterly Earnings on Wednesday

Dominari (NASDAQ:DOMH) is expected to issue its resultson Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $30.0760 million for the quarter.

Dominari Trading Up 7.6%

Shares of DOMH stock opened at $3.39 on Wednesday. The firm has a fifty day moving average price of $3.00 and a 200 day moving average price of $3.96. The company has a market cap of $76.65 million, a P/E ratio of -0.87 and a beta of 0.69. Dominari has a 12 month low of $2.68 and a 12 month high of $8.40.

Dominari Dividend Announcement

The company also recently announced a special dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be paid a dividend of $0.31 per share. The ex-dividend date is Friday, May 15th.

Institutional Investors Weigh In On Dominari

A number of institutional investors and hedge funds have recently bought and sold shares of DOMH. Geode Capital Management LLC lifted its position in Dominari by 2.9% in the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock valued at $361,000 after acquiring an additional 1,866 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Dominari in the second quarter valued at about $158,000. Vanguard Group Inc. raised its holdings in shares of Dominari by 8.0% in the third quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock valued at $2,452,000 after buying an additional 25,694 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Dominari in the third quarter valued at about $771,000. Finally, Millennium Management LLC purchased a new stake in shares of Dominari in the third quarter valued at about $213,000. 42.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DOMH has been the subject of a number of analyst reports. Weiss Ratings downgraded shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, January 12th. Wall Street Zen downgraded shares of Dominari from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.